广东方盛融科药业

Guangdong Fangsheng Rongke Pharmaceutical is a research-driven biotechnology company based in Guangzhou, China, and a subsidiary of the publicly traded Hunan Fangsheng Pharmaceutical. The company focuses on the development of innovative small molecule drugs and improved new drug formulations (Class 2) across therapeutic areas such as cardiovascular disease and oncology. Its lead program, Rosuvastatin Mesylate for Injection, is an improved formulation targeting hypercholesterolemia and is currently in late-stage clinical trials. Additionally, the company is advancing early-stage innovative assets like FSRK-001 for the treatment of solid tumors. Fangsheng Rongke leverages the manufacturing and commercialization expertise of its parent group to bring high-value pharmaceutical products to the Chinese market.